Biotimize
In an unprecedented model in the country, Biotimize opens a laboratory to development of active biological inputs in Brazil Company is the first to work under GLP certification in Brazil to operate in the “as a service” model (CDMO) and will be the only one in South America to offer an end-to-end production service from… Continue reading Biotimize’s R&D Center inauguration
We are used to talk about Good Manufacturing Practice (GMP), however, have you thought the importance of the Good Laboratory Practice (GLP)? While GLP and GMP serve different purposes and address different stages of product development and manufacturing, they are both essential components of the regulatory framework governing the biopharmaceutical industry. GMP ensures the consistent… Continue reading Good Laboratory Practice (GLP)
During the ASCO (American Society of Clinical Oncology) and BIO International conventions, our partner PHP Biotech released to the world its impressive in vitro results from the nanobody Pepcrotament that we are developing and manufacturing on their behalf. Pepcrotament enhances the production of the wild p53 structure and normal cells are not being damaged. … Continue reading Biotimize’s Results: PHP Biotech
Cell line development is a critical step in the production of biopharmaceuticals, especially in the manufacturing of therapeutic proteins like monoclonal antibodies. This process involves selecting and cultivating cells capable of producing the desired protein in large quantities and with the highest quality. The efficiency of this development directly impacts the time, cost, and success… Continue reading The Importance of the Beacon Equipment for Cell Line Development: A Biotimize Exclusive in Brazil
Drug development, especially for biologic therapies, is a costly and complex process. Biologics, derived from living cells, require advanced technologies and highly controlled environments to manufacture. Capital costs, which include the construction of facilities, procurement of equipment, and maintaining a production infrastructure, play a significant role in these expenses. According to recent research, the mean… Continue reading How a CDMO Can Help Reduce Capital Costs for Companies Developing Biologic Drugs
Biotimize - Biotechnology as a Service is committed to complying with the laws that protect the privacy of the data of its employees, partners and the general public.
See how we deal with the information collected:
What are the data types?
Personal data:
”Information related to the identified or viral person”, for example: first name, last name, date of birth, personal documents, home or business address, telephone, email and IP address.
Sensitive Personal data:
These are the data that refer to racial or ethnic origin, religious conviction, political opinion, union affiliation or organization of a religious, philosophical or political nature. Sensitive personal data as well are those related to health or sex life, genetic or biometric data.
What data does our Company collect?
Our company handles data from employees, partners and service providers, being duly compliant with the LGPD.
On the website, the company collects data through the voluntary and consensual completion of forms, e-books and contact to receive the newsletter.
Is there automatic data collection? Biotimize - Biotechnology as a Service does not automatically collect data in each access to the website.
How do they use my data?
The personal data provided by users who fill in the forms are used solely to provide feedback at the user's request (individual or legal entity interested in our company's products and services).
Once the service is completed, such data is deleted.
Have you got any questions?
Talk to the Data Protection Manager (DPO) by email: dpo@biotimize.com.br
You will be able to clarify doubts related to the processing of personal data.
